Coffee Colored Serum, Adverse Reaction of Eltrombopag.

Carlos Rodríguez Rojas, Celia Juez Santamaría, Oscar David Pons Belda, Emilia Moreno Noguero

Open access · greenAbstract readCase Reports

In one paragraph

Article in EJIFCC, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.3field-weighted citation impact, top 34% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Eltrombopag-Induced Serum Pigmentation in Severe Aplastic Anemia: A Case Report.Acta haematologica · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Carlos Rodríguez RojasClinical Analyses Department, Hospital Can Misses, Eivissa, Spain.

Celia Juez SantamaríaPharmacy Department, Hospital Can Misses, Eivissa, Spain.

Oscar David Pons BeldaClinical Analyses Department, Hospital Can Misses, Eivissa, Spain.

Emilia Moreno NogueroClinical Analyses Department, Hospital Can Misses, Eivissa, Spain.

Hospital Can Misses · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serum index and macroscopic characteristics of samples can give valuable information and should be interpreted as a result. Following centrifugation of the sample, on gross inspection it was observed that the serum had a brown color. After ruling out the main causes that can cause a brown coloration, such as intravascular hemolysis or high concentrations of methemoglobin, it was noted that the patient was receiving a high-dose of Eltrombopag therapy. Eltrombopag is a non-peptide thrombopoietin receptor agonist approved for the treatment of severe aplastic anemia (SAA). The drug in solution has a brown color and at high concentrations it is capable of changing the color of the serum and may have different effects in different assays of laboratory. This article describes the case of a patient with brown serum due to the consumption of high doses of Eltrombopag that started to cause cutaneous hyperpigmentation.

Indexed as

Brown serumclinical laboratorycutaneous hyperpigmentationEltrombopag

Identifiers

PMID37868084

PMCPMC10588078

OpenAlexW4387865707

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.